Harold H. Shlevin, PhD
President and Chief Executive Officer, Tikvah Therapeutics

Dr. Shlevin is the President & CEO of Tikvah Therapeutics, Inc., an Atlanta, GA pharmaceutical enterprise focused on late-stage development of compounds with strong intellectual property protection and significant market potential. Tikvah Therapeutics, Inc. primary development focus is on the novel application of existing therapeutic entities where clinical proof of concept is already well-established and its commercial focus is in the specialty areas of CNS - psychiatry and neurology. This strategy is designed to minimize the risk of r&d while maximizing the commercial potential of its product assets. Its leadership team is comprised of individuals with a demonstrated record of accomplishments in development, approval and commercialization of pharmaceutical products and it is supported a by a strong network of scientific advisors.

Prior to this, Dr. Shlevin most recently held the position of Global Senior Vice President of Solvay Pharmaceuticals, SA reporting directly to the head of the worldwide pharmaceuticals business. This role, including global P&L responsibility, functioned to assure the company effectively managed its regulatory, safety, quality and external affairs activities worldwide. He was a member of the Solvay Pharmaceuticals SA Board of Directors responsible for the worldwide pharmaceutical business, and also remained a member of the Board of Directors of the US pharmaceuticals business. Shlevin joined Solvay Pharmaceuticals as Senior Vice President of Business Development and Scientific Affairs in August 1998 and served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. from June 2000 to January 2006. He was also a member of the global management committee, an officer of the corporation, Chairman of the Board of its independently owned and operated subsidiary Unimed Pharmaceuticals, Inc., and a member of the board of Solvay Draka, a specialty plastic company with interest in medical device applications. Under Dr. Shlevin's leadership as CEO, Solvay Pharmaceuticals, Inc. experienced a period of record growth in revenue and profits; these achievements were underpinned by aggressive acquisitions and research and development. Importantly, a long-standing adverse regulatory situation was resolved without fines or consent decrees.

Dr. Shlevin has over twenty-five years of diverse healthcare business-related experience, involving virtually every aspect of the pharmaceutical business from research and development through commercial operations. His past industry experience includes leadership roles at G.D. Searle and Co., Ciba-Geigy Corporation, and he was a founder of Ciba Vision Ophthalmics.

After earning a bachelor's degree from Boston University, Shlevin earned a master's and doctorate from University of Rochester Medical School. He holds post-doctoral degrees in pharmacology and physiology from the Mayo Graduate School of Medicine, Mayo Foundation and Mayo Clinic where he also served as Assistant Professor of Pharmacology and Physiology. He served on the Board of Directors of the Pharmaceutical Research and Manufacturers Association of America and the National Pharmaceutical Council. He currently serves on the Board of Directors of the American Foundation for Suicide Prevention, the Board of Advisors of Morehouse School of Medicine, the Board of Directors of Cardiome Pharma Corporation (NASDQ: CRME), Vice Chair of Georgia Bio and its Executive Committee.